U.S. Markets close in 4 hrs 22 mins

Portage Biotech Inc. (PRTG)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
28.75+0.84 (+3.01%)
As of 11:10AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close27.91
Open28.38
Bid28.55 x 800
Ask28.90 x 1800
Day's Range28.38 - 28.80
52 Week Range13.84 - 41.41
Volume3,550
Avg. Volume10,475
Market Cap347.398M
Beta (5Y Monthly)143.89
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
    Newsfile

    Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

    Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG" Westport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading ...

  • Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
    Newsfile

    Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

    - Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - April 8, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" ...

  • Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics
    Newsfile

    Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

    - The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 monthsWestport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune ...